QurieGen

QurieGen is a Dutch biotech startup, founded in 2022 as a spin-off from Radboud University, that specializes in accelerating oncology drug development. The company has developed a proprietary technology called QuRIE-seq, which enables the simultaneous, high-resolution quantification of multiple molecular layers—including mRNA, membrane proteins, intracellular proteins, and phosphoproteins—at a single-cell level. By integrating this unique multi-omics data with machine learning, QurieGen constructs predictive, mechanistic virtual cell models. This approach moves beyond traditional static, averaged biological snapshots to provide a dynamic, time-resolved understanding of how cells respond to drug perturbations. The platform is designed to decode complex signaling networks, thereby helping researchers identify drug mechanisms, overcome resistance, and improve the precision of therapeutic interventions.

This technology addresses critical inefficiencies in the pharmaceutical industry, such as high costs, long development timelines, and the high failure rate of clinical trials. By providing pharmaceutical partners with high-quality, actionable data, QurieGen aims to derisk the drug discovery process and enable more informed decision-making earlier in the R&D pipeline. The company’s lab-in-the-loop methodology allows it to partner with biopharmaceutical firms on end-to-end projects, from experimental design to biological insight, supporting the identification of successful drug candidates and effective combinations. Through its combination of data-driven insights and advanced modeling, QurieGen seeks to transform drug development into a more predictable and human-relevant engineering challenge.